1. Italy Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
PharmaNutra S.p.A.

PharmaNutra S.p.A.

70.50
EUR
-1.20
(-1.67%)
2.16EPS
40.53P/E
839.74MMarket Cap
Nov 09Next Earn
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.78
4.72
3.9
4.83
5.56
6.04
7.11
8.62
10.51
12.16
13.87
15.03
Basic EPS, GAAP
0.37
0.55
0.62
0.88
0.87
1.45
1.42
1.56
1.33
1.73
2.09
2.16
Free Cash Flow per Basic Share
- -
0.53
0.49
0.58
0.74
1.04
1.08
-3.29
-0.12
1.68
1.71
1.71
Dividend per Share
- -
0.18
0.17
0.33
0.5
0.46
0.67
0.71
0.8
0.85
1
- -
Book Value per Share
0.59
0.96
1.97
2.52
2.91
3.9
4.66
5.28
5.66
6.47
7.45
7.28
Tangible Book Value per Share
0.17
0.36
1.52
2.04
2.42
3.36
4.09
3.05
3.31
4.05
4.9
4.69
Basic Weighted Avg Shares
7
7
10
10
10
10
10
10
10
10
10
10
Sales/Revenue/Turnover
26
33
38
47
54
58
69
83
101
117
133
144
Operating Margin (%)
16.47
19.21
19.24
26.09
23.32
23.27
27.81
27.9
23.26
24.06
22.77
21.65
Depreciation Expense
- -
1
1
1
1
2
1
1
3
4
3
3
Net Income, GAAP
3
4
6
9
8
14
14
15
13
17
20
21
Effective Tax Rate (%)
36.46
36.38
31.24
27.8
30.69
- -
26.79
35.74
44.83
39.06
34.03
33.28
Profit Margin (%)
9.8
11.75
15.96
18.28
15.7
24.06
20.01
18.04
12.65
14.22
15.05
14.4
Working Capital
3
3
17
21
21
29
39
33
31
38
42
36
LT Debt
3
2
3
2
2
1
6
14
23
20
15
14
Total Equity
4
7
19
24
28
38
45
51
54
62
71
70
Return on Invested Capital (%)
- -
34.55
32.29
31.1
26.37
- -
28.88
23.68
16.55
19.12
21.94
23.79
Return on Capital (%)
- -
36.98
33.65
31.57
26.37
- -
30.36
25.12
17.57
20.51
23.04
24.75
Return on Common Equity (%)
- -
71.59
46.83
39.31
32.16
42.73
33.26
31.34
24.36
28.49
29.96
31.69

Capital Structure

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
5
5
5
LT Borrowings
14
13
12
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
10
10
Market Capitalization
520
754
840

Working Capital

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
73
75
69
Cash, Cash Equivalents & STI
31
29
15
Accounts Receivable, Net
21
28
35
Inventories
9
8
9
Total Current Liabilities
31
31
34
Payables & Accruals
- -
- -
- -
ST Debt
5
5
5
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
39.51%
13.63%
14.66%
Free Cash Flow
- -
-398.64%
1.59%
Net Income, GAAP
25.58%
8.45%
20.44%
Sales/Revenue/Turnover
17.71%
17.89%
13.83%
Total Cash Common Dividend
- -
17.43%
17.36%

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
24
33
28
32
117
2025
27
36
33
37
133
2026
33
41
- -
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.27
0.65
0.44
0.36
1.73
2025
0.25
0.7
0.5
0.63
2.09
2026
0.36
0.68
- -
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.85
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Roberto Lacorte
Full Time Employees
128
Sector
Health technology
Industry
Pharmaceuticals: other
Address
Via delle Lenze 216/B Pisa PI Italy 56122
IPO Date
Jul 18, 2017
Website
pharmanutra.it
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Pharmanutra S.p.A. Pharmanutra S.p.A. (PHN.MI) specializes in the research, development, production, and marketing of nutraceutical products, nutritional supplements, medical devices, and pharmaceutical active ingredients. The company offers iron, folic acid, vitamin, omega-3, and microelement-based supplements under brands including SiderAL, Gestalys, Bonecal, Novomega, and Dikappa2 for treating anemia, nutritional deficiencies, and preventing cardiovascular disorders; anti-inflammatory products for joint and musculoskeletal pain relief under the Cetilar brand; medical devices, generic drugs, and over-the-counter products through Junia Pharma; infant nutritional supplements; and bioactive ingredients via Alesco for pharmaceutical, agri-food, and nutraceutical industries. Founded in 2003 and headquartered in Pisa, Italy, Pharmanutra S.p.A. operates through the PharmaNutra Group, which includes subsidiaries such as Akern S.r.l., Athletica Cetilar S.r.l., PharmaNutra U.S.A. Corp., and PharmaNutra España, with products distributed in over 80 countries via direct sales, distributors, pharmacies, and online channels targeting consumer, pharmaceutical, and healthcare markets primarily in Europe and North America. Recent developments include the 2024 merger by incorporation of Junia Pharma S.r.l. and Alesco S.r.l.; a November 2024 distribution agreement with Sigma Lifesciences for SiderAL r products in Canada, completing North American expansion; an October 2024 agreement with an international advisor for a U.S. subsidiary growth plan; the launch of new nutritional supplement ApporTal Boost in June 2025; a partnership with Giro d'Italia as Official Nutrition Partner through 2027 announced in May 2025; and the acquisition of Akern in 2025 contributing to new business units, alongside a share buyback program initiated in October 2025.